PO-1044: Dose escalation in dominant intraprostatic lesion with MRIguided HDR brachytherapy in localized prostate cancer  by Mascarenhas, F. et al.
3rd ESTRO Forum 2015                                                                                                                                         S563 
 
scoring criteria. Patients also completed the Expanded 
Prostate Cancer Index Composite (EPIC) questionnaires for 
quality of life every 6 months. 
Results: Median follow-up was 80 months (range 4.9-132 
months). Median patient age was 68.5 years (range 51-83 
years). The majority of patients had T1c or T2 clinical stage, 
60.8% had a Gleason score of 7 and median PSA was 9.3 
ng/mL (range 3-24.4 ng/mL). Recurrence was observed in 
five patients which lead to a BF rate of 9.8%. The 5-year 
cancer specific survival (CSS) and overall survival (OS) were 
100% and 87.9%, respectively. The 11-year estimated CSS and 
OS were 85.3% and 67.8%, respectively. The Fisher's exact 
test showed that the only significant predictor BF was 
Gleason score of 8. Late toxicity included grade 2 
gastrointestinal (GI) toxicity in 2 (5.9%) patients and no grade 
3 GI toxicity; genitourinary toxicity grades 2 and 3 in 3 (9%) 
and 5 (14.7%) patients, respectively; as well as erectile 
function grades 2 and 3 in 27 (31%) patients. 
Conclusions: These long-term outcomes confirm that 
hypofractionated EBRT plus HDR brachytherapy boost 
provides good results in terms of treatment-related toxicity 
and biochemical control for intermediate to high risk 
prostate cancer. We believe these findings support the use of 
HDR brachytherapy as a valuable dose escalation modality for 
localized prostate cancer.  
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Purpose/Objective: To develop a model for PSA antigen 
values at one year among patients treated with 
intraoperative planning based I-125 prostate brachytherapy 
(IOPB). 
Materials and Methods: In this retrospective cohort study, 
407 patients who received treatment with low dose rate 
prostate brachytherapy for prostate adenocarcinoma and had 
at least one measured PSA value within the first year post 
treatment were divided into four groups: those with PSA 
values ≥ 3, those with PSA <3 and ≥2, those with PSA <2 and ≥ 
1 and those with 1 year PSA value <1 measured between 10.5 
and 14.5 months post implantation. Ordinal regression 
analysis was then performed between patient, tumor and 
treatment characteristics. 
Results: A total of 870 patients with low to low-tier 
intermediate risk prostate cancer were treated with IOPB 
between June 2003 and July 2014. 460 patients had PSA 
measurements within the first year post treatment. 53 of 
these received hormone therapy and were excluded from this 
analysis. This cohort had median age 63.3 years (range: 45-
81) and pre-treatment PSA of 5.82ng/mL (0.34-13.8). Almost 
all patients were Gleason 6 (74%) or Gleason 7 (26%). 310 
patients had T1c disease (71 had T2a and 9 had T2b). Median 
percentage of positive biopsy tissue was 5.0% (0.5-60), 
median time from biopsy to treatment was 5.5 months (0.33-
70.2). Median prostate volume was 33.89cc. Median source 
activity was .437mCi (0.343-0.481) and a median of 72 seeds 
(41-99) in 26 needles (19-77) were used. Median D90 was 
190.0Gy (137.5-202.0). One year PSA values were measured 
at a median of 12 months (10.5-14.5). Median PSA at this 
time was 0.77 (0.04-17.36).  32 patients (8%) had a PSA ≥3; 
35 (9%) had PSA <3, ≥2; 87 (21%) had PSA <2, ≥1 and most 
patients 254 (62%) had PSA <1. On ordinal modeling, PSA 
response was independent of gland volume, Gleason score, 
clinical stage, time from initial biopsy to implantation, seed 
activity and number of needles and seeds used. There was no 
relationship between PSA at one year and implant V90, V200 
or D90. Older patients had significantly lower 1 year PSA 
values; median ages 65.1 (46.5-81.0), 62.1 (50.4-79.5), 60.5 
(47.1-80.3) and 58.1 (45.1-74.2) years for each of the 1 year 
PSA groups respectively (p<0.001). Also, both implant V150 
and initial PSA values showed direct correlation with 
measured PSA values at 1 year (p<0.001 and p=0.004 
respectively).  
Conclusions: PSA response at 1 year post intraoperative plan 
based prostate brachytherapy is dependent on patient age, 
initial PSA and implant V150. These factors may be useful 
when counseling patients on expectations regarding PSA 
response post prostate brachytherapy. Although early 
prediction of low dose rate brachytherapy treatment failure 
remains elusive, initial prediction of treatment response may 
allow better determination of which patients will require 
closer follow-up post implantation. Our results are reassuring 
to patients that parameters other than failure may be 
responsible for PSA values >1 at 1 year. 
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Purpose/Objective: Local failures after external beam 
radiotherapy (EBRT) are frequent at the site of the original 
dominant intraprostatic lesion(DIL). The concept of dose 
painting of dominant intraprostatic lesion (DIL) using a 
multiparametric MRI-guided HDR brachytherapy (HDRBT) for a 
synchronous simultaneous boost was applied as a strategy for 
tumor dose escalation. Our proposal is to analyze the 
dosimetric goals for CTV or prostate+extracapsular 
extension+3mm margins, for DIL, conformity index and organs 
at risk (OAR). 
Materials and Methods: We have analyzed the dosimetric 
studies of 8 patients with intermediate and high risk prostate 
cancer treated with MRI-guided HDRBT 15Gy single fraction 
and hypofractionated volumetric modulated arctherapy 
37.5Gy in 15 fractions.  
Brachytherapy included ultrasound guided catheter insertion, 
hyaluronic acid in Denonvilier space and the treatment 
planning was based on rigid image fusion of staging mpMRI, 
postimplant T2 sequence MRI and CT planning. The DIL, CTV 
and OaR were contoured and dosimetric parameters for DIL, 
CTV and normal tissues were analyzed. 
 
 
Results: The average prostate V100% and D90, DIL V125%, 
urethra D0,1cc, bladder D2cc, and rectum D2cc have been 
assessed. 
 
 
The inclusion of MRI information allows to administer a 
synchronous integrated boost to the DIL while dose in the 
remaining prostate can be decreased, keeping a substantial 
dose to guarantee high tumor control probability and 
simultaneously allows to spare the OAR. 
Conclusions: The treatment planning of HDRBT guided by 
mpMRI image registered with postoperative T2-sequence MRI 
and CT in localized prostate cancer seems to be an 
attractive, effective and safe strategy for detecting and 
localizing cancer within prostate and to allow accurately 
dose escalation of the DIL without compromising the 
prostatic dose coverage or the sparing of the urethra, rectum 
and bladder. 
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Purpose/Objective: The correct quantification of the 
uncertainties associated with the radiation process is part of 
the normal procedures for external radiation therapy. 
However, in the area of brachytherapy this concept is less 
developed in practice, and it is usually underestimated 
arguing that applicators, if moving, they would do it in 
solidarity to the tumor. This explanation does not consider 
the possible impact on other organs or other sources of 
uncertainty. In the HDR prostate technique, a correct 
identification of the tips of the needles in ultrasound imaging 
is key to limiting the dosimetric discrepancies between the 
plan and reality. At our institution, an isotropic margin of 
3mm on the prostate is applied except in the rectum 
direction. On this PTV an inverse optimization is performed 
with a 3 mm dwell step resolution and allowing the source to 
stop only within the PTV. After approval of the plan the 
patient is treated in a HDR unit with a 60Co source. 
To evaluate the goodness of the margin is the aim of this 
work 
Materials and Methods: To assess the level of accuracy of a 
method that does not apply a corrective action, an implant of 
a prostate phantom was performed under exactly the same 
conditions of a real implant . An implant type was performed 
on a prostatic phantom trying to locate all tips in the same 
plane, for later acquire a 1mm resolution CT study in order to 
assess the real situation of the needles with respect to the 
organs. The actual positions of the tips of the 15 needles 
were measured in the CT scan, obtaining the histogram and 
then adjusted to a normal distribution. Assuming that in a 
real treatment, the probability of errors in identifying the 
ends follow this Gaussian, deviations were randomly drawn in 
5 patients (preliminary) to quantify the dosimetric deviations 
on the representative dosimetric parameters for prostate , 
PTV, rectum and urethra. 
Results: Normal distribution: µ=0mm; s= 2.12 mm 
The differences between the plans that contain all the tips in 
the same plane and subjected to deviations are summarized 
in the following chart 
PTV D100 D99 D90 V200 V150 V100 V95 
Mean 
(%) 0.24 -0.41 -0.68 0.05 -0.11 -0.60 -0.57 
SD (%) 2.66 1.23 1.30 0.25 0.75 1.18 1.09 
Prostate D100 D99 D90 V100 V95 V150 V200 
Mean 
(%) 1.45 0.41 0.31 0.15 0.32 0.29 0.26 
SD (%) 1.71 1.16 1.40 0.14 0.61 1.26 1.17 
Urethra D1% D2% 
Mean (%) 1.52 0.60 
SD (%) 1.00 0.77 
Rectum D2cc D1cc D0.1cc 
